{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:20Z","timestamp":1787020760145,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2021YJ0454"],"award-info":[{"award-number":["2021YJ0454"]}]},{"name":"Sichuan Science and Technology Program","award":["2019YFS0003"],"award-info":[{"award-number":["2019YFS0003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32070049"],"award-info":[{"award-number":["32070049"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81872907"],"award-info":[{"award-number":["81872907"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Science and Technology of China","award":["2021YFA1301900"],"award-info":[{"award-number":["2021YFA1301900"]}]},{"name":"Sichuan University start-up funding","award":["20822041D4057"],"award-info":[{"award-number":["20822041D4057"]}]},{"name":"Science and Technology Plan Project of Sichuan Province","award":["2020YFSY0025"],"award-info":[{"award-number":["2020YFSY0025"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-5-075"],"award-info":[{"award-number":["2021-I2M-5-075"]}]},{"name":"the National Major Scientific and Technological Special Project for Significant New Drugs Development","award":["2018ZX09201018-021"],"award-info":[{"award-number":["2018ZX09201018-021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing potential beyond MM, which encouraged us to develop new anti-CD38 mAbs to meet clinical needs. In this study, we developed a novel humanized anti-CD38 antibody, FTL004, which exhibited enhanced pro-apoptotic ability and negligible binding to red blood cells (RBCs). FTL004 presented a better ability to induce direct apoptosis independent of Fc-mediated cross-linking against lymphoma and MM cell lines as well as primary myeloma cells derived from MM patients. For instance, FTL004 induced RPMI 8226 cells with 55% early apoptosis cells compared with 20% in the isatuximab-treated group. Of interest, FTL004 showed ignorable binding to CD38 on human RBCs in contrast to tumor cells, even at concentrations up to 30\u00a0\u03bcg\/mL. Furthermore, with an engineered Fc domain, FTL004 displayed stronger antibody-dependent cellular cytotoxicity (ADCC)\u00a0against CD38+\u2009malignant cells. In vivo MM and non-Hodgkin lymphoma tumor xenograft models showed that FTL004 possessed an effective anti-tumor effect. Cryo-electron microscopy structure resolved two epitope centers of FTL004 on CD38: one of which was unique while the other partly overlapped with that of isatuximab. Taken together, FTL004 distinguishes it from other CD38 targeting mAbs and represents a potential candidate for the treatment of MM and non-Hodgkin lymphoma.<\/jats:p>","DOI":"10.1186\/s13045-022-01395-0","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T03:03:08Z","timestamp":1672282988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Guangbing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianda","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhuai","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lantu","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"11","key":"1395_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s42255-020-00298-z","volume":"2","author":"CCS Chini","year":"2020","unstructured":"Chini CCS, Peclat TR, Warner GM, Kashyap S, Espindola-Netto JM, de Oliveira GC, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD(+) and NMN levels. Nat Metab. 2020;2(11):1284\u2013304.","journal-title":"Nat Metab"},{"issue":"12","key":"1395_CR2","first-page":"1408","volume":"10","author":"K Mehta","year":"1996","unstructured":"Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J Off Publ Fed Am Soc Exp Biol. 1996;10(12):1408\u201317.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"issue":"1","key":"1395_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW van de Donk","year":"2016","unstructured":"van de Donk NW, Janmaat ML, Mutis T, van Lammerts Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95\u2013112.","journal-title":"Immunol Rev"},{"key":"1395_CR4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0229","author":"V Bhatnagar","year":"2017","unstructured":"Bhatnagar V, Gormley NJ, Lola L, et al. FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. Oncologist. 2017. https:\/\/doi.org\/10.1634\/theoncologist.2017-0229.","journal-title":"Oncologist"},{"issue":"12","key":"1395_CR5","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.3324\/haematol.2021.279487","volume":"106","author":"Y Ofran","year":"2021","unstructured":"Ofran Y. Daratumumab: new indications revolving around \u201coff-targets.\u201d Haematologica. 2021;106(12):3032\u20133.","journal-title":"Haematologica"},{"issue":"Supplement_1","key":"1395_CR6","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1182\/blood-2019-128238","volume":"134","author":"ER Fedyk","year":"2019","unstructured":"Fedyk ER, Idamakanti N, Chen J, Estevam J, Palumbo A. The binding of CD38 therapeutics to red blood cells and platelets subverts depletion of target cells. Blood. 2019;134(Supplement_1):3136.","journal-title":"Blood"},{"key":"1395_CR7","doi-asserted-by":"publisher","DOI":"10.1159\/000495773","author":"E Werle","year":"2019","unstructured":"Werle E, Ziebart J, Wasmund E, Eske-Pogodda K. Daratumumab interference in pretransfusion testing is overcome by addition of daratumumab Fab fragments to patients\u2019 plasma. Transfus Med Hemother. 2019. https:\/\/doi.org\/10.1159\/000495773.","journal-title":"Transfus Med Hemother"},{"key":"1395_CR8","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","volume":"9","author":"G Lancman","year":"2018","unstructured":"Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, et al. Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies. Front Immunol. 2018;9:2616.","journal-title":"Front Immunol"},{"issue":"21","key":"1395_CR9","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood.2020006200","volume":"136","author":"M Naeimi Kararoudi","year":"2020","unstructured":"Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, et al. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020;136(21):2416\u201327.","journal-title":"Blood"},{"issue":"6","key":"1395_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12257-021-0024-2","volume":"26","author":"P Jebamani","year":"2021","unstructured":"Jebamani P, Sriramulu DK, Jung ST, Lee S-G. Structural study on the impact of S239D\/I332E mutations in the binding of Fc and Fc\u03b3RIIIa. Biotechnol Bioprocess Eng. 2021;26(6):985\u201392.","journal-title":"Biotechnol Bioprocess Eng"},{"key":"1395_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2022.114564","volume":"307","author":"Y Hong","year":"2022","unstructured":"Hong Y, Guo H, Wei M, Zhang Y, Fang M, Cheng T, et al. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. J Virol Methods. 2022;307: 114564.","journal-title":"J Virol Methods"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01395-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T03:06:10Z","timestamp":1672283170000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01395-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01395-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"24 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human subject studies were approved by the Ethnic Committee of West China Hospital of Sichuan University. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qing Li, Ying Huang, Fanxin Ma, Xianda Zhang, Shuang Liu, Zhouning Yang, Pengyu Chen, Ziqing Ren, Meng Yu, and Feng Qu are employees at Sound Biopharmaceuticals Co., Ltd. No potential conflicts of interest were disclosed by the other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}